Dr. Kenneth M. Borow, MD

President, Chief Medical and Strategic Development Officer

Dr. Borow is the President, Chief Medical and Strategic Development Officer of Encorium Group, Inc. He is a Harvard-trained internist, pediatrician, adult cardiologist and pediatric cardiologist with over 30 years of clinical research experience. As Professor of Medicine and Pediatrics at the University of Chicago, he was the author of more than 100 manuscripts dealing with heart failure, ischemic cardiovascular disease, systemic and pulmonary hypertension, cardiac and vascular imaging, and pharmacologic therapy for left ventricular dysfunction. He also oversaw a large cardiovascular research group that included centers in the US, United Kingdom, Norway, Israel, and South Africa. As Director of the Cardiovascular Non-Invasive Imaging Program at the University of Chicago, he was responsible for clinical and research studies involving multiple advanced imaging techniques.

Immediately prior to coming to Encorium Group, Dr. Borow was responsible for Clinical Research Operations in the United States and Puerto Rico for Merck Research Laboratories. In this role, he oversaw clinical research studies for over 200 different protocols conducted at more than 2,500 investigative sites. His group was a involved in clinical development programs for 38 new drug entities including Cozaar®/Hyzaar®, Zocor®, Tirofiban®, Singulair®, Maxalt®, Fosamax®, and numerous vaccines.

Since coming to the Company, Dr. Borow has been involved in the design and conduct of more than 50 clinical trials, many of them multinational in scope. For example, he helped design and oversee the conduct of Pfizer's landmark REVERSAL and CAMELOT-NORMALISE studies and Mylan Laboratories' nebivolol development program. Over the past decade, Dr. Borow has been a senior consultant to numerous pharmaceutical and biotechnology companies as well as venture capital firms relative to study design and conduct of trials in heart failure, atherosclerosis, systemic hypertension, hyperlipidemias, thorough QT/QTc interval evaluation, cardiovascular imaging, diabetes, pulmonary arterial hypertension, atrial and ventricular arrhythmias, osteoporosis and multiple vaccines.